Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 3/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845603 | 1.00 | NTSR1 (0.54) | NTSR1NTSR2F2OXTROPRD1 | |
| SCHEMBL25845492 | 0.96 | NTSR1 (0.54) | NTSR1NTSR2F2OXTROPRD1 | |
| SCHEMBL25845887 | 0.95 | OPRD1 (0.56) | NTSR1NTSR2F2OPRD1EP300 | |
| SCHEMBL14930602 | 0.94 | AGTR2 (0.55) | NTSR1NTSR2F2OXTRSLC6A2 | |
| SCHEMBL14930600 | 0.90 | NMBR (0.58) | F2NPY2RNPY4RNPY5R | |
| SCHEMBL25845686 | 0.90 | NMBR (0.58) | F2NPY2RNPY4RNPY5R | |
| SCHEMBL14930601 | 0.90 | NMBR (0.58) | F2NPY2RNPY4RNPY5R | |
| SCHEMBL25845490 | 0.88 | SLC6A2 (0.55) | NTSR1NTSR2F2OXTRSLC6A2 | |
| SCHEMBL25845909 | 0.85 | NMBR (0.66) | F2NPY2RNPY4RNPY5R | |
| SCHEMBL25845917 | 0.85 | NMBR (0.66) | F2NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | EGFR, ERBB2, ERBB3 | NTSR1 265/4885NTSR2 455/4885F2 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.